[go: up one dir, main page]

ZA200803924B - Use of a CB1 antagonist for treating side effects and negative symtoms of schizophrenia - Google Patents

Use of a CB1 antagonist for treating side effects and negative symtoms of schizophrenia

Info

Publication number
ZA200803924B
ZA200803924B ZA200803924A ZA200803924A ZA200803924B ZA 200803924 B ZA200803924 B ZA 200803924B ZA 200803924 A ZA200803924 A ZA 200803924A ZA 200803924 A ZA200803924 A ZA 200803924A ZA 200803924 B ZA200803924 B ZA 200803924B
Authority
ZA
South Africa
Prior art keywords
symtoms
schizophrenia
antagonist
negative
side effects
Prior art date
Application number
ZA200803924A
Other languages
English (en)
Inventor
Black Mark
Borowsky Beth
Rogacki Nancy
Senyah Yaw
Stevens Rachel
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ZA200803924B publication Critical patent/ZA200803924B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200803924A 2005-12-08 2008-05-08 Use of a CB1 antagonist for treating side effects and negative symtoms of schizophrenia ZA200803924B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74843405P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
ZA200803924B true ZA200803924B (en) 2009-10-28

Family

ID=37964962

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803924A ZA200803924B (en) 2005-12-08 2008-05-08 Use of a CB1 antagonist for treating side effects and negative symtoms of schizophrenia

Country Status (23)

Country Link
US (1) US20080221078A1 (xx)
EP (1) EP1962834A2 (xx)
JP (1) JP2009518423A (xx)
KR (1) KR20080073737A (xx)
CN (1) CN101321523A (xx)
AR (1) AR056846A1 (xx)
AU (1) AU2006321907A1 (xx)
BR (1) BRPI0619541A2 (xx)
CA (1) CA2632673A1 (xx)
CR (1) CR9957A (xx)
DO (1) DOP2006000273A (xx)
EC (1) ECSP088505A (xx)
IL (1) IL191888A0 (xx)
MA (1) MA30090B1 (xx)
NO (1) NO20082923L (xx)
PE (1) PE20071092A1 (xx)
RU (1) RU2008127491A (xx)
SV (1) SV2008002929A (xx)
TN (1) TNSN08205A1 (xx)
TW (1) TW200803839A (xx)
UY (1) UY29995A1 (xx)
WO (1) WO2007067617A2 (xx)
ZA (1) ZA200803924B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AU2008307572A1 (en) * 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
CA2709863A1 (fr) * 2007-12-18 2009-09-03 Sanofi-Aventis Derives d'azetidines, leur preparation et leur application en therapeutique
FR2925051B1 (fr) * 2007-12-18 2010-05-21 Sanofi Aventis Derives d'azetidines,leur preparation et leur application en therapeutique
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN107074841B (zh) 2014-08-11 2021-03-26 安吉恩生物医药公司 细胞色素p450抑制剂及其用途
CA2960275A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Smyd inhibitors
US10287282B2 (en) 2014-12-31 2019-05-14 Angion Biomedica Corp. Methods and agents for treating disease
BR112019003732A2 (pt) 2016-08-24 2020-02-18 Prilenia Therapeutics Development Ltd. Aplicação de pridopidina para tratamento de declínio funcional

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
CN1802351A (zh) * 2003-06-11 2006-07-12 麦克公司 被取代的3－烷基和3－链烯基氮杂环丁烷衍生物
RU2006110545A (ru) * 2003-09-02 2007-10-10 Зольвай Фармасьютикалз Гмбх (De) Новое медицинское применение избирательных антагонистов св1-рецептора
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Also Published As

Publication number Publication date
CR9957A (es) 2008-09-22
CN101321523A (zh) 2008-12-10
TW200803839A (en) 2008-01-16
AU2006321907A1 (en) 2007-06-14
RU2008127491A (ru) 2010-01-20
EP1962834A2 (en) 2008-09-03
US20080221078A1 (en) 2008-09-11
SV2008002929A (es) 2009-12-02
JP2009518423A (ja) 2009-05-07
CA2632673A1 (en) 2007-06-14
TNSN08205A1 (en) 2009-10-30
PE20071092A1 (es) 2007-12-10
AR056846A1 (es) 2007-10-24
DOP2006000273A (es) 2007-10-15
ECSP088505A (es) 2008-08-29
UY29995A1 (es) 2007-07-31
IL191888A0 (en) 2009-08-03
MA30090B1 (fr) 2008-12-01
WO2007067617A2 (en) 2007-06-14
KR20080073737A (ko) 2008-08-11
WO2007067617A3 (en) 2007-11-01
BRPI0619541A2 (pt) 2011-10-04
NO20082923L (no) 2008-09-02

Similar Documents

Publication Publication Date Title
ZA200803924B (en) Use of a CB1 antagonist for treating side effects and negative symtoms of schizophrenia
IL193014A0 (en) Methods and compositions for treating schizophrenia
PL2124999T3 (pl) Antagoniści aktywiny-actrii i zastosowania do leczenia niedokrwistości
EP1982627A4 (en) CLEANING BODY AND CLEANING TOOL
EP2080470A4 (en) CLEANING BODY AND CLEANING TOOL
IL191118B (en) Ritoxy Mav for use in the treatment of joint damage
EP1982628A4 (en) CLEANING BODY AND CLEANING TOOL
EP2023874A4 (en) METHOD FOR IDENTIFYING ACTIVE SUBSTANCES AND THEIR USE FOR THE PREVENTION OF RESTENOSIS
PL2001556T3 (pl) Związki tioniny i ich zastosowanie
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
GB0712964D0 (en) Spray masks and line markers
SI1734959T1 (sl) Spojine za zdravljenje shizofrenije in/ali glukoregulatornih nenormalnosti
GB0611115D0 (en) Compounds and their use
IL199427A (en) Radiation-protective compounds and related methods
IL192820A0 (en) Novel compounds and use thereof
GB0619611D0 (en) Compounds and their use
ZA200905465B (en) Calcium reducing agents and methods
GB0608797D0 (en) Novel agents and the use thereof
HUP0600122A3 (en) New compounds and their use
GB0617317D0 (en) Iifa 2007 Yorkshire
GB0621286D0 (en) Alternative body sling
GB0619609D0 (en) Compounds and their use
GB0603378D0 (en) Compounds and their use
GB0610888D0 (en) Compounds and their use
GB0616577D0 (en) Compounds and their use